Results 271 to 280 of about 801,078 (341)
The burden of obesity in primary care in Italy: Italian real-world overweight/obesity study (ITROS). [PDF]
Buscemi S +9 more
europepmc +1 more source
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh +18 more
wiley +1 more source
Early macronutrient intake and overweight at five years of age
Silvia Scaglioni +7 more
openalex +1 more source
Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen +7 more
wiley +1 more source
The profound impact of COVID-19 on college students' physical fitness. [PDF]
Sun J, Qiao B, Lin C.
europepmc +1 more source
Use of self-report to monitor overweight and obesity in populations: some issues for consideration
Victoria Flood +3 more
openalex +1 more source
Use of glucagon‐like peptide‐1 receptor agonists in patients with left ventricular assist devices
Key question: does GLP1‐RA therapy improve heart transplantation rates and clinical outcomes in patients with LVADs? Key findings: in this propensity score‐matched cohort study of 1068 LVAD recipients, GLP1‐RA use was associated with higher heart transplantation rates (18.9% vs.
Ramzi Ibrahim +12 more
wiley +1 more source
Association Between Serum Cobalt and Manganese Levels with Insulin Resistance in Overweight and Obese Mexican Women. [PDF]
Soto-Sánchez J +8 more
europepmc +1 more source

